Skip to main content
. 2020 May 26;34(8):2102–2112. doi: 10.1038/s41375-020-0867-0

Table 2.

CML treatment.

Variables Not discontinued Discontinued
N % N %
Medication
 Imatinib (Glivec/Gleevec or generic Imatinib) 263 (56) 242 (51)
 Nilotinib (Tasigna) 100 (21) 141 (29)
 Dasatinib (Sprycel) 88 (19) 75 (16)
 Bosutinib (Bosulif) 9 (2) 5 (1)
 Ponatinib (Iclusig) 3 (1) 1 (0)
 Interferon Alpha 0 (0) 14 (3)
 ABL001/Asciminib 0 (0) 0 (0)
 Other 9 (2) 1 (0)